Literature DB >> 28078192

Etanercept in the treatment of refractory SAPHO syndrome.

Lei Zhang1, Zhaomeng Gao1.   

Abstract

OBJECTIVE: To explore the application and efficacy of TNF-α inhibitors in the treatment of SAPHO syndrome.
METHODS: Two cases of refractory SAPHO syndrome were successfully treated with etanercept. And pain scores, laboratory parameters and functional index were used to judge the efficacies. Literature was also systemically reviewed.
RESULTS: Both patients achieved marked clinical remission. There was no obvious toxic or adverse response.
CONCLUSION: Etanercept has rapid and definite efficacies in the treatment of patients with refractory SAPHO syndrome.

Entities:  

Keywords:  SAPHO syndrome; discitis; etanercept; tumor necrosis factor-alpha

Year:  2016        PMID: 28078192      PMCID: PMC5218853     

Source DB:  PubMed          Journal:  Am J Clin Exp Immunol


  12 in total

1.  Acne conglobata and arthritis.

Authors:  R E WINDOM; J P SANFORD; M ZIFF
Journal:  Arthritis Rheum       Date:  1961-12

2.  SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.

Authors:  Jaime Vilar-Alejo; Luis Dehesa; Pilar de la Rosa-del Rey; Javier Novoa-Medina; Pedro Valerón Almazán; Néstor Santana Medina; Jesús Bastida
Journal:  Acta Derm Venereol       Date:  2010-09       Impact factor: 4.437

3.  SAPHO: disease, syndrome, or category?

Authors:  Itzhak Rosner
Journal:  J Clin Rheumatol       Date:  2002-02       Impact factor: 3.517

4.  Tumor necrosis factor-alpha blockers in SAPHO syndrome.

Authors:  Kaouther Ben Abdelghani; Delphine Gerard Dran; Jacques-Eric Gottenberg; Jacques Morel; Jean Sibilia; Bernard Combe
Journal:  J Rheumatol       Date:  2010-05-15       Impact factor: 4.666

5.  Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study.

Authors:  L L Zhang; J X Zhao; X Y Liu
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

Review 6.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

7.  Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris.

Authors:  B Björkstén; K H Gustavson; B Eriksson; A Lindholm; S Nordström
Journal:  J Pediatr       Date:  1978-08       Impact factor: 4.406

8.  [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases].

Authors:  A M Chamot; C L Benhamou; M F Kahn; L Beraneck; G Kaplan; A Prost
Journal:  Rev Rhum Mal Osteoartic       Date:  1987-03

9.  Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.

Authors:  N Pennanen; S Lapinjoki; A Urtti; J Mönkkönen
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended?

Authors:  Alexander P Rozin
Journal:  Arthritis Res Ther       Date:  2009-11-05       Impact factor: 5.156

View more
  2 in total

Review 1.  SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review.

Authors:  Hanna Przepiera-Będzak; Marek Brzosko
Journal:  Postepy Dermatol Alergol       Date:  2020-07-23       Impact factor: 1.837

Review 2.  New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors:  Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal:  J Inflamm Res       Date:  2022-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.